

CHOLESTEROL & LIPOPROTEIN


Dr Piyush B Tailor
Associate Professor
Govt. Medical College
Surat

INTRODUCTION

- The word cholesterol is derived from Greek words,
- **Chole =bile, steros =solid, ol=alcohol.**
- It is widely distributed in the body.
- It is soluble in chloroform and other fat solvents.
- It is the most important animal steroid from which other steroid compounds are formed.

Significant of Cholesterol

1. **Cell membranes:** it is a component of cell membranes
2. **Nerve conduction:** it is a poor conductor of electricity, and helps to insulate nerve fibers.
3. **Bile acids and bile salts:**
4. **Steroid hormones:** Glucocorticoids, Androgens and Estrogens are synthesized from cholesterol.
5. **Vitamin D3:** it is synthesized from 7-dehydrocholesterol.
6. **Esterification**
 - Cholesterol esterified to fatty acids = Cholesterol esters.
7. **Atherosclerosis**
 - Increase level of abnormal cholesterol lead to CAD & CVD.



Cholesterol


ABSORPTION OF CHOLESTEROL

- Absorption needs miceller formation.
- Inside the mucosal cell, cholesterol is re-esterified and incorporated into chylomicrons.
- The chylomicrons reach the blood stream through lymphatics.
- This dietary cholesterol reaches the liver through chylomicrons remnants.
- Plant sterols (sitosterol) decrease absorption of cholesterol.


BIOSYNTHESIS OF CHOLESTEROL

- Cholesterol is synthesised from Acetyl CoA.
- Partly Cytoplasm & Partly in Endoplasmic reticulum.
- Primary site: Liver (~1g/d)
- Secondary sites: Adrenal cortex, ovaries, testes
- All nucleated cells can synthesize cholesterol, including arterial walls.

SYNTHESIS OF CHOLESTEROL




- **HMG CoA (3-hydroxy-3-methylglutaryl-CoA)** is present in both cytosol as well as mitochondria of liver.
- Mitochondrial pool = for ketone body synthesis
- Cytosolic pool = for cholesterol synthesis.



**HMG CoA
reductase**



CoA


$2\text{NADPH} + 2\text{H}^+ \rightarrow 2\text{NADP}^+$



HMG CoA

Mevalonate





Regulation of Cholesterol Synthesis

- Rate limiting enzyme is HMG CoA reductase.

1. Regulation at transcription

- Long term regulation
- Regulation of transcription of the gene of HMG CoA reductase.
- Increase Cholesterol
 - Suppress transcription of the gene for HMG CoA reductase
 - Synthesis of cholesterol decrease.
- Low Cholesterol
 - Induce transcription of the gene for HMG CoA reductase
 - Synthesis of cholesterol increase.
- Patient taking “Statin” drug
 - Decrease cholesterol
 - Induce gene for HMG CoA reductase = Increase Enzyme Conc.

Regulation of Cholesterol Synthesis

2. Covalent modification of enzyme:

- Phosphorylation of enzyme = Inactive enzyme.
- Dephosphorylation of enzyme = Active enzyme.


3. **Insulin and thyroxine** increase the activity .


4. **Cortisol and Glucagon** decrease its activity.

5. Drugs :


- ‘Statin’ group of drugs are competitive inhibitors of HMG CoA reductase.

e.g. Atorvastatin. Simvastatin






Major sources of liver cholesterol



EXCRETION OF CHOLESTEROL

- Average diet = 300 mg of cholesterol/day.
- Body synthesise = 700 mg of cholesterol/day.
- Total 1000mg
- About 500 mg of cholesterol = excreted through bile.
- 95% of this cholesterol is reabsorbed from intestines.
- Plant sterols = inhibit the reabsorption of cholesterol.

Was Mona Lisa suffering from
hypercholesterolemia?




Plasma Lipid

Plasma Lipid

- Total plasma lipid is 400-600 mg/dl.
- One-third is cholesterol
- One-third is TGs
- One-third is phospholipid.
- **Lipoproteins (Lp) = Lipid + Protein**
- **Apolipoprotein =** The protein part of lipoprotein.

CLASSIFICATION OF LIPOPROTEINS

- Five major types:
 1. Chylomicrons
 2. VLDL or pre beta lipoproteins
 3. IDL or broad beta lipoproteins
 4. LDL or beta lipoproteins
 5. HDL or alpha lipoproteins
- Free fatty acids (FFA) or non-esterified fatty acids (NEFA) are complexed with albumin, not generally considered as lipoproteins.



Chylomicron



VLDL



IDL




LDL



HDL

Lipoprotein




Lipoprotein

- Outer Part made up of
 - Polar part of proteins
 - Polar heads of phospholipids
 - Cholesterol.
- This inner core consists
 - Hydrophobic TAGs
 - Tails of phospholipids.
- The apoproteins increase the solubility of lipids.


Separation by ultracentrifugation

- Fat is less dense than water; so fat floats on water.
- Lipoproteins
 - High lipid content
 - Low density
 - Floats on centrifugation.
- Lipoproteins
 - High protein content
 - High density
 - Sediment easily

ULTRACENTRIFUGATION



ELECTROPHORESIS



Positive

VLDL = very low density lipoproteins; IDL= intermediate density lipoproteins; LDL = low density lipoproteins; HDL= high density lipoproteins; FFA = free fatty acid

Lipoprotein Types & Composition

Lipoprotein	Source	Diameter (nm)	Density (g/mL)	Composition		Main Lipid Components	Apolipoproteins
				Protein (%)	Lipid (%)		
Chylomicrons	Intestine	90-1000	<0.95	1-2	98-99	Triacylglycerol	A-I, A-II, A-IV, ^a B-48, C-I, C-II, C-III, E
Chylomicron remnants	Chylomicrons	45-150	<1.006	6-8	92-94	Triacylglycerol, phospholipids, cholesterol	B-48, E
VLDL	Liver (intestine)	30-90	0.95-1.006	7-10	90-93	Triacylglycerol	B-100, C-I, C-II, C-III
IDL	VLDL	25-35	1.006-1.019	11	89	Triacylglycerol, cholesterol	B-100, E
LDL	VLDL	20-25	1.019-1.063	21	79	Cholesterol	B-100
HDL	Liver, intestine, VLDL, chylomicrons					Phospholipids, cholesterol	A-I, A-II, A-IV, C-I, C-II, C-III, D, ^b E
HDL ₁		20-25	1.019-1.063	32	68		
HDL ₂		10-20	1.063-1.125	33	67		
HDL ₃		5-10	1.125-1.210	57	43		
Pre β -HDL ^c		<5	>1.210				A-I
Albumin/free fatty acids	Adipose tissue		>1.281	99	1	Free fatty acids	

Apo-lipoprotein Function


- Structural role
 - Apo B
- Enzyme cofactor
 - C-II for Lipoprotein Lipase
 - A-I for Lecithine Cholesterol Acyl Transferase (LCAT)
- Enzyme inhibitor
 - A-II and C-III for Lipoprotein lipase
 - C-I for Cholesterol ester transferase protein
- Act as ligand with receptor
 - A-I for HDL receptor
 - B-100 & E for LDL receptor
 - E for LDL receptor related protein (LRP)
- A-IV & D = No clear function
- Apo D is believed to be important factor in neurodegenerative disorders

Apoprotein	Component of	Function
Apo A-I	HDL-1	Activation of LCAT
Apo A-II	HDL-3	Inhibits LCAT, Stimulates hepatic lipase
Apo B-100	LDL, VLDL	Binds LDL receptor
Apo B-48	Chylomicrons	Major Structural component
Apo C-I	Chylomicrons, VLDL	Activation of LCAT
Apo C-II	Chylomicrons, VLDL	Activates extrahepatic Lipoprotein Lipase in vessels walls
Apo C-III	Chylomicrons, VLDL	Inhibit Lipoprotein Lipase
Apo E	IDL, VLDL, Chylomicrons	Ligand for hepatic uptake
Apo Lp (a)	Lp(a)	Attached to B-100, Impair fibrinolysis. Inhibit plasminogen


1. CHYLOMICRONS

Chylomicrons Synthesis :

- Formed in the intestinal mucosal cells
- Secreted into the lymphatic system.
- They are **rich in TGs**.
- In intestine mucosa phase
 - Contain only Apo A & Apo-B-48
- In the blood, when transported intestine to other tissue,
 - Added Apo C-II and Apo E
 - Through HDL.
- If the lipemic serum is kept overnight in the refrigerator, chylomicrons rise as a creamy layer to the top.



Chylomicrons Metabolism



Chylomicrons Metabolism

- In Adipose tissue & Skeletal muscle
- Half life in blood is 1 hour.
- Endothelial layer of capillaries of adipose tissue, muscles and heart; but **Not in liver.**
 - Has lipoprotein lipase
 - Apo-C-II of chylomicron activates the LpL.
 - Hydrolyzes Triglyceride = FA + Glycerol.
 - Muscle or Adipose tissue take up Fatty acids.

Chylomicrons Metabolism

- Heparin
 - Release LpL from the tissues
 - Lipemia is cleared.
 - Post-heparin lipolytic activity.
- Deficiency of Apo C-II
 - Decreased LpL activity
 - Accumulation of chylomicrons & VLDL in blood.
- Insulin increases LpL activity.
 - Type -1 Diabetes Mellitus - Deficiency of Insulin
 - Decrease LpL activity
 - Accumulation of chylomicrons & VLDL in blood.

Chylomicrons Metabolism

- **Liver takes up “Chylomicrons remnants”:**
 - TG content decreased
 - Chylomicrons shrink in size.
 - Containing **Apo-B48 and Apo-E**
 - Taken up by hepatic cells by receptor mediated endocytosis.
 - **Apo-E binds to the Hepatic receptors.**
- **Function:**
 - Transport form of dietary TGs from intestines to the adipose tissue for storage ; and to muscle or heart for their energy needs.

VLDL Synthesis


Nascent VLDL

- Synthesized **in liver** from Glycerol, Fatty acid & Cholesterol.
- **With Apo-B-100, C-I and E.**

VLDL

- Plasma HDL add apolipoprotein
- **Apo-C-II and Apo-E** added to Nascent VLDL

Very Low Density Proteins Metabolism



VLDL Metabolism

- Half-life of VLDL in serum =1-3 hrs.
- Reach the peripheral tissues
- Apo C-II activates Lipoprotein Lipase (LpL)
- Liberated fatty acid is taken by Adipose tissue and Muscle.
- This remnant called IDL , contains
 - Less of Triglyceride
 - More of cholesterol.
- Major fraction of IDL further loses triglyceride and Converted to LDL.
- **Lipoprotein Cascade Pathway.**
 - Conversion of VLDL to IDL & to LDL
- IDL is taken up by the hepatic receptors.

VLDL Function


- VLDL carries **Triglycerides** (endogenous triglycerides) **from liver to peripheral tissues** for energy needs.

Low Density Lipoprotein

- Cholesterol rich lipoprotein
- Containing **only Apo-B-100**.
- Most of LDL particles are derived from VLDL.
- Half Life of LDL = 2 days

Low Density Lipoprotein Metabolism

- **LDL receptors**
 - Present on all cells
 - Most abundant in hepatic cells.
 - Located in specialized regions - **Clathrin Coated Pits.**
- **Apo-B-100 binds to the receptor**
- Receptor-LDL complex
- Internalized by Endocytosis.
- Vesicles fuse with lysosomes.
- Lysosomal enzymes
 - Degrade the apoproteins of the LDL
 - Hydrolyze the cholesterol esters to free cholesterol.
- Free receptors return to the membrane surface to bind new LDL.



Low Density Lipoprotein Function

- LDL transports **cholesterol from liver to the peripheral tissues.**
- Positive correlation with cardiovascular diseases.
- About 75% of the plasma cholesterol is incorporated into the LDL particles.

LDL and Atherosclerosis

- **LDL Modification – Glycation.**
- **Oxidized LDL.**
- LDL infiltrates through arterial walls
- Taken up by macrophages = Scavenger cells.
- **“FOAM CELL”**
- Starting event of Atherosclerosis
- Coronary Artery Disease.
- **Bad Cholesterol & Lethally Dangerous Lipoprotein.**
- “Small dense LDL” (sdLDL) = Worst fraction of LDL, associated with coronary artery diseases.


Apo Lipoprotein-A = Apo-A

- Constituent of HDL.
- **Anti Atherogenic.**

Lipoprotein (a) = Lp(a)

- Associated with LDL.
- **Highly Atherogenic**
- **Attached to apo-B-100** by a disulfide bond.
- Lp(a) has significant homology with plasminogen.
- So it interferes with plasminogen activation
- **Impairs fibrinolysis.**
- This leads to unopposed intravascular thrombosis and possible myocardial infarction.

Lp(a) and Plasminogen



High Density Lipoprotein Metabolism

- Transport cholesterol from peripheral tissue to liver.
- HDL = Apo A-I, Apo A-II, Apo-C , Apo-E
- **Major reservoir of Apo-C & Apo-E**

High Density Lipoprotein Metabolism


- Intestine cell synthesized Component of HDL
- Nascent HDL – Discoid in shape.
- Apo-A-I of HDL activates **LCAT** .
 - Lecithin - Component of phospholipid bilayer of HDL disc.
 - 2nd carbon of lecithin - one molecule of PUFA.
 - PUFA transferred to cholesterol to form cholesterol ester.
- Esterified cholesterol internalized to HDL disc.
 - **Cholesterol Efflux Regulatory Protein – ABC Protein**
 - **ATP Binding Cassette (ABC) Transporter-A1**
- Internalization continuous till HDL became spherical
- Filled with lots of cholesterol esters = **“Mature HDL”** spheres

High Density Lipoprotein Metabolism

- **“Mature HDL” Spheres (HDL-3)**
- Taken by liver cells
- Apo-A-I mediated receptor mechanism.
- Hepatic lipase hydrolyzes HDL .
 - Phospholipid
 - Cholesterol ester
 - Triglyceride
- These cholesterol Utilized for
 - Bile acid synthesis

High Density Lipoprotein Metabolism

- **“Mature HDL”** Spheres (**HDL-3**)
- Some remain circulation
- Cholesterol Ester Transferase Protein (CETP)
 - Transfer to Cholesterol ester from HDL to
 - VLDL
 - IDL
 - LDL
 - Transfer Triglyceride into HDL
 - So More cholesterol can be taken up from periphery
- **HDL-2** = Higher TG and Spherical Shape
- Hydrolysed by Hepatic Triglyceride Lipase




High Density Lipoprotein Function

- Transport **cholesterol from peripheral tissue to liver.**
- Later excreted through bile.
- Called **Reverse cholesterol transport**
- Only excretory route of cholesterol is the bile.
- Excretion of cholesterol needs prior esterification with PUFA.
- **PUFA is anti-atherogenic.**

HDL Subfraction

- HDL-1
- **HDL-2 is Good – Anti-atherogenic**
 - HDL-2a
 - HDL-2b
- HDL-3
 - HDL-3a
 - HDL-3b
 - HDL-3c



Free Fatty Acid

- Also known as **Non-Esterified Fatty Acids (NEFA)**.
- It is complexed with **albumin** in plasma.
- Derived from lipolysis of TGs
- Transported
 - Heart
 - Skeletal muscle
 - Liver
 - Other soft tissues.
- Oxidized to supply energy
- Incorporated into tissue lipids by esterification.
- Half life of FFAs = only 1-2 minutes.

Plasma Lipid Profile

- Total - Cholesterol
- HDL - Cholesterol
- LDL - Cholesterol
- Triglycerides
- Apo-B level
- Apo-A-I level
- Lp(a) level
- Cholesterol / HDL Cholesterol Ratio
- LDL / HDL Cholesterol Ratio

Hypo-Lipoproteinemia

- **Abeta Lipoproteinemia :**
- Decrease All Apo-B containing lipoproteins
- Defect in **Microsomal Triglyceride Transfer Protein .**
- TG can not incorporated into VLDL and chylomicrons.
- LDL is absent.
- No Fat soluble vitamins absorption.
- Mental & Physical retardation.
- Blood TGs, cholesterol & phospholipids = Extremely low.
- Blindness may occur due to degenerative changes in retina.
- Erythrocytes have spiny projections (**Acanthocytes**).

Hypo-Lipoproteinemia

Hypo-Alphalipoproteinemia :

- Autosomal dominant condition
- HDL is decreased
- Increased risk of coronary artery diseases.

Tangier Disease

- Benign autosomal dominant condition.
- **ATP Binding Cassette Transporter-1 (ABC-1)** defective
- Defect in the efflux of cholesterol from cells to HDL
- Reduction of HDL levels
- Alpha band is absent in electrophoresis.
- Cholesterol esters are accumulated in tissues.
- **Manifestation**
 - Large orange yellow tonsils
 - Muscle atrophy
 - Recurrent peripheral neuropathies
 - Atherosclerosis.

Frederickson's classification of Hyper-lipoproteinemia

Type	Elevated Lipoprotein	Cholesterol	TG	Metabolic defect	Feature
Type -I	Chylomicron	N	Very High	Lipoprotein Lipase / Apo C-II deficiency	Xanthoma Hepatomegally
Type -IIA	LDL	High	N	LDL receptor defect Increase Apo B	Xanthoma Atherosclerosis
Type -IIB	LDL & VLDL	High	High	Increase Apo B	Corneal arcus
Type -III	Broad beta – VLDL & Chylomicron	High		Abnormal Apo-E / Increase Apo C-II	Palmar Xanthoma, Vascular disease
Type -IV	VLDL	N	High	Over production of VLDL, Increase Apo C-II	Associate with DM, Heart disease & Obesity
Type -V	VLDL Chylomicron	N	High	Secondary to other causes	IHD

Type I- Hyperchylomicronemia

- **Lipoprotein lipase deficiency**
- **Apo C-II deficiency**
- Manifestation in Young Age
- Severe Lipemic sample
- Lipemia retinalis
- Post Heparin Hepativ Lipolytic Absent

Type IIA- Primary Familial Hypercholesterolemia

- LDL receptor defect in Liver & Peripheral
 - Reduce number of LDL receptor deficiency
 - Defective binding of B-100 to LDL receptor.
 - Substitution of glutamine for arginine at 3500th AA in Apo B-100
 - **Familial Defect Apo B**
 - Receptor-LDL complex is not internalized
- Elevation of LDL
- Survival upto second decade of life
- Due to ischemic heart disease.

Type IIA- Secondary Familial Hypercholesterolemia

- Hypothyroidism
- Diabetes mellitus
- Nephrotic syndrome
- Cholestasis

Type IIB- Hypercholesterolemia

- Excessive production of Apo-B
- Elevation of both cholesterol and TGs
- LDL and VLDL are elevated.
- The abnormalities are manifested only by the third decade of life.

Type III- Hyperlipoproteinemia

- Rare
- Broad Beta Band observed in electrophoresis
- Increase LDL and IDL .
- Palmar Xanthomas and Vascular disease
- **Floating Beta disease**
- **Broad Beta disease**

Type IV- Familial Endogenous Type

- Over production of VLDL
- Over production of TGs by liver.
- Manifestation in 4th decade
- Increase Apo C-II level

Type V- Hyperlipoproteinemia

- Increase VLDL and Chylomicron
- Secondary to other disease
 - Obesity
 - Excessive Alcoholic ingestion
 - Renal Failure
 - Pancreatitis
- Other causes of Hyperlipoproteinemia
 - Hepatic Lipase defect
 - LCAT defect
 - Lp(a) excess.
 - Wolman's disease

Atherosclerosis

Pathogenesis of Atherosclerosis

- **Free Radical** convert LDL into **oxidized LDL**
- Oxidized LDL **deposited in the subintimal** regions of arteries.
- Accumulate into **Macrophages**
- Macrophages become overloaded with cholesterol
- **“Foam cells”**
- In Early stages - Reversible if LDL get decrease.
- **Atherosclerotic plaque** - Narrowing of Vessel.
- **Fibrous proliferation** - due to liberation of inflammatory mediator from macrophages & platelets.
- **Narrow lumen = Turbulent = Thrombosis**
- Ischemia of the tissue = **Infarction** = Death of tissue

Risk Factor for Atherosclerosis

Modifiable Risk Factor

- Increase high carbohydrate diet
- Increase high cholesterol containing diet
- Trans Fatty acid intake
- Western Pattern diet
 - Packed food
- Sedentary life style
- Obesity
- Addiction
 - Smoking – Alcohol

Risk Factor for Atherosclerosis

Modifiable Risk Factor

- Familiar history
- Polluted Air
- Radiation – Gamma radiation , X-ray , UV rays
- Chemical
- Drugs
- Medical Condition
 - Diabetes Mellitus
 - Hypertension
 - Chronic inflammatory disease
 - Dyslipidemia
 - Hyperhomocysteinemia

Risk Factor for Atherosclerosis

- Dyslipidemia
 - Increase Total cholesterol
 - Normal : < 199 mg %
 - Borderline : 200 – 239 mg%
 - Abnormal : > 240 mg%
 - Increase LDL cholesterol
 - Normal : < 130 mg %
 - Borderline : 130 – 160 mg%
 - Abnormal : > 160 mg%
 - Decrease HDL cholesterol
 - Good : > 60 mg %
 - Normal : 40 – 60 mg%
 - Abnormal : < 40 mg%

Risk Factor for Atherosclerosis

- Dyslipidemia
 - Total Cholesterol / HDL ratio
 - Risk > 3.5
 - LDL:HDL ratio
 - Risk > 2.5
 - Increase Triglyceride
 - Increase Lipoprotein-a
 - Ratio of Apo B:A-I
 - Normal = < 0.4 Very good
 - Risk = > 1.4

Risk Factor for Atherosclerosis

Non - Modifiable Risk factor

- Advance age
- Genetic abnormalities
- Chronic stress

Prevention of Atherosclerosis

1. Reduce Dietary cholesterol

- Eggs and meat contain high cholesterol so it should be avoided.

2. Adequate intake of Vegetables oils and PUFA:

- Vegetable oils - Sunflower oil
- Fish oils contain PUFA.

3. High Fiber diet

- Green leafy vegetables – Salad – Fruits
- Reduce reabsorption of bile salts
- Decrease Cholesterol

4. Avoid High Carbohydrate diet with high glycemic index

5. Avoid Western Pattern Diet – Pack food

6. Avoid cigarette smoking & Alcohol ingestion

Prevention of Atherosclerosis

7. Regular Exercise

- To reduce obesity

8. Bile acid binding resins (cholestyramine)

- Decrease the reabsorption of bile acids.

9. HMG CoA reductase inhibitors

- Statin drugs – Atorvastatin , Levostatin

10. Nicotinic acid

- To reduce triglyceride and VLDL level

11. Anti-Platelet


- Aspirin - To prevent thrombus formation


12. Anti-oxidants

- Decrease oxidation of LDL

13. Take regular medication for other medical disease – HT ,DM

Bile Acid Synthesis





Thank You